Abstract
A family of proteases known as caspases is a key element in the proteolytic machinery involved in apoptosis or programmed cell death. Apart from their involvement in cell death, caspases are also associated with the developmental process and other normal functions of adult organisms. Caspases are named such because they constitute a family of cysteine proteases which always cleave an Asp residue in their substrates. Stroke results from a rapid malfunctioning of the brain due to lack of blood supply and is a major health threat producing mortality and morbidity. Majority of strokes are ischemic (80 % of all strokes) and the rest are hemorrhagic. Both forms of divergent cell death mechanisms, necrosis, and apoptosis are observed at different spatial region of ischemic attack. Involvement of multiple caspases in stroke has been documented with caspases 1, 3, 8, 9, and 11 playing major roles. Many neurodegenerative diseases result from loss of functional neurons from the brain through enhanced death of neurons. Neurodegenerative diseases are usually late onset and progressive. Among the most common neurodegenerative disorders in aging populations worldwide, Alzheimer’s disease (AD) and Parkinson’s disease (PD) definitely warrant mentioning. Abnormal protein deposits in specific regions of the brain give rise to both these diseases triggering reactive oxygen species formation and mitochondrial dysfunction. Caspases are activated by these changes resulting in loss of neurons through cell death. In this review we provide a brief overview of the involvement of caspases in diseases associated with the impairment of brain function.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rupinder SK, Aulakh KG, Singh M (2007) Cell suicide and caspases. Vascul Pharmacol 46: 383–393
Manjo G, Joris I (1995) Apoptosis, oncosis and necrosis An overview of cell death. Am J Pathol 146: 3–15
Kanduc D, Mittelman A, Serpico R (2002) Cell death: apoptosis versus necrosis. Int J Oncol 21: 165–170
Fernandez-Flores A, Aguilera B, Yau P et al (2002) An old meaning of the word apoptosis. Lancet 359: 1072
Kerr JFR, Wyllie AH, Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging implication in tissue kinetics. Br J Cancer 26: 239–257
Saraste A, Pulkki K (2000) Morphological and biochemical hallmarks of apoptosis. Cardiovascul Res 45: 528–537
Zimmerman KC, Bonzon C, Green DR (2002) The machinery of programmed cell death. Pharmacol Therapeut 92: 57–70
Yuan J, Yankner BA (2000) Apoptosis in the nervous system. Nature 407: 802–809
Hengartner MO (2000) The biochemistry of apoptosis. Nature 407: 770-776
Shi, Y (2002) Mechanism of caspase activation and inhibition during apoptosis. Mol Cell 9: 459–470
Yuan J, Shaham S, Ledoux S et al (1993) The C elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. Cell 75: 641–652
Alnemri ES, Livingston DJ, Nicholson DW et al (1996) Human ICE/CED-3 protease nomenclature Cell 87: 171
Hengartner MO, Horvitz HR (1994) C elegans Cell Survival Gene ced-9 Encodes a Functional Homolog of the Mammalian Proto-Oncogene bcl-2. Cell 76: 665-676
Thornberry NA, Bull HG, Calaycay JR et al (1992) A novel heterodimeric cysteine protease is required for interleukin-1βprocessing in monocytes. Nature 356:768–774
Thornberry NA, Lazebnik Y (1998) Caspases: enemies within Science 281:1312-1316
Stegh AH, Peter ME (2002) Apoptosis and caspases. Cardiol Clin 19: 13–29
Cerrethi DP, Kozlosky CJ, Mosely B et al (1992) Molecular cloning of the interleukin – 1 beta converting enzyme Science 256: 97–100
Faucheu C, Diu A, Chan A et al (1995) A novel human protease similar to the interleukin 1 beta-converting enzyme induces apoptosis in transfected cells. EMBO J 14: 1914–1922
Munday NA, Vaillancourt, JP, Ali A et al (1995) Molecular cloning and proapoptotic activity of ICE rel II and ICE rel III members of ICE/Ced 3 family of cysteine proteases. J Biol Chem 270: 15870–15876
Chang HY, Yang X (2000) Proteases for cell suicide: functions and regulation of caspase. Microbiol Mol Biol Rev 64: 821–846
Bergeron L, Perez GI, Macdonald G (1998) Defects in regulation of apoptosis in caspase 2 deficient mice. Genes Develop 12: 1304–1309
Fernandes AT, Armstrong RC, Krebs J et al (1996) In vitro activation of CPP32, and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FADD like domains. Proc Natl Acad Sci USA 93: 7464–7469
Duan H, Orth K, Chinnaiyan AM et al (1996) ICE/LAP6, a novel member of the ICE/ced 3 gene family, is activated by the cytotoxic T cell protease Granzyme. J Biol Chem 271: 16720–16724
Vilta P, Kaufmann SH, Earnshaw WC (1997) Caspases and caspase inhibitors. Trends Biochem Sci 22: 388–393
Sadowski DK, Coy JF, Mier W et al (2002) Caspases—their role in apoptosis and other physiological processes as revealed by knock out studies. Archiv Immun Therap Expl 50: 19–34
Thornberry NA (1998) Caspases: key mediators of apoptosis. Chem Biol 5: 97-103
Srinivasula SM, Hegde R, Saleh A et al (2001) A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 410:112-116
Prior FP, Salvesen SG (2004) The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J 384: 201–232
Muzio M, Stockwell BR, Stennicke HR et al (1998) An induced proximity model of caspase-8 activation. J Biol Chem 273: 2926–2930
Hofmann K (1999) The modular nature of apoptotic signaling proteins. Cell Mol Life Sci 55:1113–1128
Eberstadt M, Baohua Huang B, Chen Z et al (1998) NMR structure and mutagenesis of the FADD (Mort1) death-effector domain. Nature 392: 941–945
Yang J, Liu X, Bhalla K, et al (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129-1132
Green D, Kroemer G (1998) The central executioners of apoptosis: caspases or mitochondria? Trends Cell Biol 8: 267-271
Green DR, Reed JC (1998) Mitochondria and apoptosis. Science 281:1309-1312
Acehan D, Jiang X, Morgan DG et al (2002) Three-dimensional structure of the apoptosome: implications for assembly, procaspase-9 binding, and activation. Mol Cell 9: 423-432
Nicholson DW, Thornberry NA (1997) Caspases: killer proteases. Trends Biochem Sci 22: 299-306
Ashkenazi A, Dixit VM (1998) Death receptors: signaling and modulation. Science 281: 1305-1308
Garg AK, Aggarwal BB (2002) Reactive oxygen intermediates in TNF signaling. Mol Immunol 39: 509-517
Mirkes PE (2002) Warkany lecture: to die or not to die, the role of apoptosis in normal and abnormal mammalian development. Teratol 65: 228-239
Yin XM (2000) Bid, a critical mediator for apoptosis induced by the activation of Fas/TNF-R1 death receptors in hepatocytes. J Mol Med 78: 203-211
Kaufman RJ (1999) Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Develop 13: 1211-1233
Ferri KF, Kroemer G (2001) Organelle-specific initiation of cell death pathways. Nature Cell Biol 3: 255-263
Nakagawa T, Yuan J (2000) Cross-talk between two cysteine protease families Activation of caspase-12 by calpain in apoptosis J Cell Biol 150: 887-94
Lamkanfi M, Declercq W, Kalai M et al (2002) Alice in caspase land A phylogenetic analysis of caspases from worm to man. Cell Death Diff 9: 358-361
Rao RV, Castro-Obregon S, Frankowski H et al (2002) Coupling endoplasmic reticulum stress to the cell death program An Apaf-1-independent intrinsic pathway. J Biol Chem 277: 21836-21842
Hacki J, Egger L, Monney L et al (2000) Apoptotic crosstalk between the endoplasmic reticulum and mitochondria controlled by Bcl-2. Oncogene 19: 2286-2295
Trapani JA (1998) Dual mechanisms of apoptosis induction by cytotoxic lymphocytes. Intl Rev Cytol 182: 111-192
Konno R, Igarashi T, Okamoto S et al (1999) Apoptosis of human endometrium mediated by perforin and granzyme B of NK cells and cytotoxic T lymphocytes Tohoku. J Expl Med 187:149-155
Sutton VR, Wowk ME, Cancilla M et al (2003) Caspase activation by granzyme B is indirect, and caspase autoprocessing requires the release of proapoptotic mitochondrial factors. Immunity 18:319-329
Mandemakers W, Morais VA, De Strooper B (2007) A cell biological perspective on mitochondrial dysfunction in Parkinson disease and other neurodegenerative diseases. J Cell Sci 120: 1707-1716
Reddy PH (2011) Abnormal tau, mitochondrial dysfunction, impaired mitochondrial transport of mitochondria, and synaptic deprivation in Alzheimer’s disease. Brain Res 1415:136-148
Meredith SC (2005) Protein denaturation and aggregation: Cellular responses to denatured and aggregated proteins. Ann N Y Acad Sci 1066:181-221
Forno LS(1996) Neuropathology of Parkinson’s disease. J Neuropathol Expl Neurol 55:259–272
Cookson MR (2009) α-Synuclein and neuronal cell death. Mol Neurodegen 4:9
Latchoumycandane C, Anantharam V, Jin H et al (2011) Dopaminergic Neurotoxicant 6-OHDA Induces Oxidative Damage through Proteolytic Activation of PKCδ in Cell Culture and Animal Models of Parkinson’s Disease. Toxicol Appl Pharmacol 256: 314–323
Yan MH, Wang X, Zhu X (2013) Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. Free Radic Biol Med 62:90–101. doi:pii: S0891-5849(12)01823-0. 10.1016/j.freeradbiomed.2012.11.014. [Epub ahead of print]
Moussa CE, Wersinger C, Tomita Y et al (2004) Differential cytotoxicity of human wild type and mutant alpha-synuclein in human neuroblastoma SH-SY5Y cells in the presence of dopamine. Biochemistry 43:5539-5550
Cannon JR, Greenamyre JT (2010) Neurotoxic in vivo models of Parkinson’s disease recent advances. Prog Brain Res 184:17–33
Yamada M, Kida K, Amutuhairea W et al (2010) Gene disruption of caspace-3 prevents MPTP-induced Parkinson’s disease in mice Biochem Biophys Res Commun 402: 312–318
Viswanath V, Wu Y, Boonplueang R et al (2001) Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced Parkinson’s disease. J Neurosci 21:9519–9528
Han BS, Hong H, Choi W et al (2003) Caspase-Dependent and -Independent Cell Death Pathways in Primary Cultures of Mesencephalic Dopaminergic Neurons after Neurotoxin Treatment. J Neurosci 23:5069 –5078
Tanaka Y, Engelender S , Igarashi S et al (2001) Inducible expression of mutant α- synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Gen 10: 919-926
Smith WW, Jiang H, Pei Z (2005) Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alpha-synuclein-induced toxicity Hum Mol Gen 14 (24) 3801–3811
Hartmann A, Hunot S, Michel PP et al (2000) Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s disease. Proc Natl Acad Sci USA 97:2875–80
Tatton NA (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s disease. Expl Neurol 166:29–43
Ho CC, Hardy J Rideout HJ et al (2009) The Parkinson Disease Protein Leucine-Rich Repeat Kinase 2 Transduces Death Signals via Fas-Associated Protein with Death Domain and Caspase-8 in a Cellular Model of Neurodegeneration. J Neurosci 29:1011–1016
Reddy PH, Manczak M, Mao P et al (2010) Amyloid beta and mitochondria in aging and Alzheimer’s disease: implications for synaptic damage and cognitive decline J Alz Dis 20 (Suppl 2): S499-S512
LaFerla FM, Green KN, Oddo S (2007) Intracellular amyloid-beta in Alzheimer’s disease. Nature Rev Neurosci 8:499–509
Awasthi A, Matsunaga Y, Yamada T (2005) Amyloid-beta causes apoptosis of neuronal cells via caspase cascade, which can be prevented by amyloid-beta-derived short peptides. Expl Neurol 196 : 282–289
Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Ann Rev Neurosci 24:1121–1159
Oddo S, Caccamo A, Shepherd JD et al (2003) Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39:409–421
Rohn TT, Vyas V, Hernandez-Estrada T et al (2008) Lack of pathology in a triple transgenic mouse model of Alzheimer’s disease after overexpression of the anti-apoptotic protein Bcl-2. J Neurosci 28:3051–3059
Couturier J, Morel M, Pontcharraud R et al (2010) Interaction of double stranded RNA-dependent protein kinas (PKR) with the death receptor signaling pathway in amyloid beta (Abeta)-treated cells and in APPSLPS1 knock-in mice. J Biol Chem 285: 1272-1282
Zhu X, Chen C, Dan Y et al (2012) Diammonium Glycyrrhizinate Upregulates PGC-1a and Protects againstAb1–42-Induced Neurotoxicity. PLoS One 7:e35823
Fossati S, Ghiso J, Rostagno A (2012) TRAIL death receptors DR4 and DR5 mediate cerebral microvascular endothelial cell apoptosis induced by oligomeric Alzheimer’s Aβ. Cell Death Dis (2012) 3: e321; doi:101038/cddis201255
Picone P, Carrotta R, Montana G et al (2009) Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. Biophys J 96(10) : 4200-4211
Graham RK, Ehrnhoefer DE, Hayden MR (2011) Caspase-6 and neurodegeneration. Trends Neurosci 34:646-656
Li M, Ona VO, Guegan C et al (2000) Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288:335–339
Ona VO, Li M, Vonsattel JP et al (1999) Inhibition of caspase-1 slows disease progression in a mouse model of Huntington’s disease. Nature 399:263–267
Rohn TT (2010) The role of caspases in Alzheimer’s disease; potential novel therapeutic opportunities. Apoptosis 15: 1403-1409
Yang L, Sugama S, Mischak RP et al (2004) A novel systemically active caspase inhibitor attenuates the toxicities of MPTP, malonate, and 3NP in vivo. Neurobiol Dis 17:250–259
Caserta TM, Smith AN, Gultice AD et al (2003) Q-VD-OPh, a broad spectrum caspase inhibitor with potent antiapoptotic properties. Apoptosis 8:345–352
Braun JS, Prass K, Dirnagl U et al (2007) Protection from brain damage and bacterial infection in murine stroke by the novel caspase-inhibitor Q-VD-OPH. Expl Neurol 206:183–191
Sims NR, Muyderman H (2010) Mitochondria, oxidative metabolism and cell death in stroke. Biochim Biophys Acta 1802: 80–91
Donnan G A, Fisher M, Macleod M et al (2008) Stroke Lancet 371: 1612–1623
Kalaria RN (2012) Risk factors and neurodegenerative mechanisms in stroke related dementia. Panminerva Medica 54:139–148
Sharp FR, Jickling GC, Stamova B et al (2011) Molecular markers and mechanisms of stroke: RNA studies of blood in animals and humans. J Cerebral Blood Flow Metabol 31:1513–1531
Gupta A, Chazen JL, Hartman M et al (2012) Cerebrovascular reserve and stroke risk in patients with carotid stenosis or occlusion: a systematic review and meta-analysis. Stroke 43: 2884–2891
Elkind MSV (2006) Inflammation, atherosclerosis, and stroke. Neurologist 12: 140–148
Wardlaw JM, Zoppo G, Yamaguchi T et al (2003) Thrombolysis for acute ischaemic stroke Cochrane database of systematic reviews (Online) CD000213
Lipton P (1999) Ischemic cell death in brain neurons. Physiol Rev 79: 1431–1568
Linnik MD, Zobrist RH, Hatfield MD (1993) Evidence supporting a role for programmed cell death in focal cerebral ischemia in rats Stroke 24: 2002–2008
Charriaut-Marlangue C, Aggoun-Zouaoui D, Represa A et al (1996) Apoptotic features of selective neuronal death in ischemia, epilepsy and gp 120 toxicity. Trends Neurosci 19: 109–114
Pan J, Konstas A, Bateman B et al (2007) Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies. Neuroradiol 49: 93–102
Friedlander RM, Gagliardini V, Hara H et al (1997) Expression of a dominant negative mutant of interleukin-1 beta converting enzyme in transgenic mice prevents neuronal cell death induced by trophic factor withdrawal and ischemic brain injury. J Expl Med 185, 933–940
Friedlander RM (2000) Role of caspase 1 in neurologic disease. Arch Neurol 57 :1273–1276
Kang S J, Wang S, Hara H et al (2000) Dual role of caspase-11 in mediating activation of caspase-1 and caspase-3 under pathological conditions. J Cell Biol 149: 613–622
Green DR (2011) Immunology: A heavyweight knocked out. Nature 479:48–50
Honkaniemi J, Massa SM, Breckinridge M et al (1996) Global ischemia induces apoptosis-associated genes in hippocampus. Mol Brain Res 42:79–88
Harrison DC, Davis RP, Bond BC et al (2001) Caspase mRNA expression in a rat model of focal cerebral ischemia. Mol Brain Res 89:133–146
Hara H, Fink K, Endres M et al (1997) Attenuation of transient focal cerebral ischemic injury in transgenic mice expressing a mutant ICE inhibitory protein. J Cerebral Blood Flow Metabol 17: 370–375
Schielke GP, Yang GY, Shivers BD et al (1998) Reduced ischemic brain injury in interleukin-1 beta converting enzyme-deficient mice. J Cerebral Blood Flow Metabol 18: 180–185
Liu XH, Kwon D, Schielke et al (1999) Mice deficient in interleukin-1 converting enzyme are resistant to neonatal hypoxic-ischemic brain damage. J Cerebral Blood Flow Metabol 19: 1099–1108
Bergeron L, Perez GI, Macdonald G et al (1998) Defects in regulation of apoptosis in caspase-2-deficient mice. Genes Develop 12: 1304–1314
Troy CM, Rabacchi SA, Hohl JB et al (2001) Death in the balance: alternative participation of the caspase-2 and −9 pathways in neuronal death induced by nerve growth factor deprivation. J Neurosci 21: 5007–5016
Benchoua A, Guégan C, Couriaud C et al (2001) Specific caspase pathways are activated in the two stages of cerebral infarction. J Neurosci 21: 7127–7134
Chen J, Nagayama T, Jin K et al (1998) Induction of caspase-3-like protease may mediate delayed neuronal death in the hippocampus after transient cerebral ischemia. J Neurosci 18: 4914–4928
Le DA, Wu Y, Huang Z et al (2002) Caspase activation and neuroprotection in caspase-3- deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. Proc Natl Acad Sci USA 99: 15188–15193
Krupinski J, Lopez E, Marti E (2000) Expression of caspases and their substrates in the rat model of focal cerebral ischemia. Neurobiol Dis 7: 332–342
Namura S, Zhu J, Fink K et al (1998) Activation and cleavage of caspase-3 in apoptosis induced by experimental cerebral ischemia. J Neurosci 18: 3659–3668
Cao G, Luo Y, Nagayama T et al (2002) Cloning and characterization of rat caspase-9: implications for a role in mediating caspase-3 activation and hippocampal cell death after transient cerebral ischemia. J Cerebral Blood Flow Metabol 22:534–546
Akpan N, Troy CM (2012) Caspase Inhibitors: Prospective Therapies for Stroke Neuroscientist 19: 129-136
Martin-Villalba A, Hahne M, Kleber S et al (2001) Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke. Cell Death Diff 8, 679–686
Al-Jamal K T, Gherardini L, Bardi G et al (2011) Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. Proc Natl Acad Sci USA 108, 10952–10957
Endres M, Namura S, Shimizu-Sasamata M et al (1998) Attenuation of delayed neuronal death after mild focal ischemia in mice by inhibition of the caspase family. J Cerebral Blood Flow Metabol 18: 238–247
Akpan N, Serrano-Saiz E, Zacharia BE et al (2011) Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke. J Neurosci 31: 8894–8904
Dhuria SV, Hanson LR, Frey WH (2010) Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharmaceut Sci 99: 1654–1673
Acknowledgments
K.J. acknowledges partial support from the Dept. of Science and Technology, Fast Track Young Scientist Scheme.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Goswami, A., Sen, P., Jana, K., Raha, S. (2014). Involvement of Caspases in the Pathophysiology of Neurodegeneration and Stroke. In: Dhalla, N., Chakraborti, S. (eds) Role of Proteases in Cellular Dysfunction. Advances in Biochemistry in Health and Disease, vol 8. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-9099-9_3
Download citation
DOI: https://doi.org/10.1007/978-1-4614-9099-9_3
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-9098-2
Online ISBN: 978-1-4614-9099-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)